Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COCH NASDAQ:FEMY NASDAQ:ICU NASDAQ:VVOS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOCHEnvoy Medical$1.27+5.0%$1.49$1.15▼$3.99$27.33M2.21105,448 shs12.98 million shsFEMYFemasys$0.62-7.4%$0.88$0.61▼$1.80$20.23M-2.58339,606 shs890,876 shsICUSeaStar Medical$0.80$0.71$0.31▼$6.65$22.34M-1.043.23 million shs468,683 shsVVOSVivos Therapeutics$4.14-3.0%$4.39$1.98▼$7.95$24.39M7.03396,030 shs362,834 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOCHEnvoy Medical-10.37%-17.69%-24.84%-24.38%-56.79%FEMYFemasys-4.19%-8.11%-23.77%-33.58%-36.72%ICUSeaStar Medical-3.57%+9.59%+12.72%-38.46%-87.30%VVOSVivos Therapeutics-4.04%-10.11%-26.63%+105.29%+64.23%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOCHEnvoy Medical2.9456 of 5 stars3.55.00.00.00.73.30.0FEMYFemasys2.9641 of 5 stars3.53.00.00.02.42.50.6ICUSeaStar Medical0.3426 of 5 stars0.02.00.00.01.91.70.0VVOSVivos Therapeutics1.5076 of 5 stars2.34.00.00.02.40.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOCHEnvoy Medical 3.00Buy$9.25628.35% UpsideFEMYFemasys 3.00Buy$7.331,080.89% UpsideICUSeaStar Medical 0.00N/AN/AN/AVVOSVivos Therapeutics 2.50Moderate Buy$4.8216.34% UpsideCurrent Analyst Ratings BreakdownLatest ICU, COCH, FEMY, and VVOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/11/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $8.006/25/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.006/11/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.005/27/2025COCHEnvoy MedicalAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.25 ➝ $9.505/20/2025VVOSVivos TherapeuticsIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$2.255/20/2025VVOSVivos TherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOCHEnvoy Medical$220K124.23N/AN/A($1.39) per share-0.91FEMYFemasys$1.89M10.72N/AN/A$0.05 per share12.42ICUSeaStar Medical$140K159.54N/AN/A$0.12 per share6.67VVOSVivos Therapeutics$14.63M1.67N/AN/A$1.35 per share3.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOCHEnvoy Medical-$20.80M-$1.43N/AN/AN/A-10,961.26%N/A-236.14%N/AFEMYFemasys-$18.82M-$0.86N/AN/AN/A-1,113.72%-713.74%-152.60%N/AICUSeaStar Medical-$24.83M-$2.62N/A∞N/A-1,915.27%N/A-232.65%N/AVVOSVivos Therapeutics-$11.14M-$1.73N/AN/AN/A-76.82%-170.43%-77.82%8/20/2025 (Estimated)Latest ICU, COCH, FEMY, and VVOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025Q2 2025VVOSVivos Therapeutics-$0.39-$0.55-$0.16-$0.55$3.37 million$3.82 million8/13/2025Q2 2025ICUSeaStar Medical-$0.43-$0.18+$0.25-$0.18$0.25 million$0.34 million8/8/2025Q2 2025FEMYFemasys-$0.18-$0.16+$0.02-$0.16$0.80 million$0.41 million7/31/2025Q2 2025COCHEnvoy Medical-$0.29-$0.32-$0.03-$0.32$0.07 million$0.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOCHEnvoy MedicalN/AN/AN/AN/AN/AFEMYFemasysN/AN/AN/AN/AN/AICUSeaStar MedicalN/AN/AN/AN/AN/AVVOSVivos TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOCHEnvoy MedicalN/A0.940.74FEMYFemasys0.030.890.41ICUSeaStar MedicalN/A1.521.50VVOSVivos TherapeuticsN/A0.770.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOCHEnvoy Medical8.59%FEMYFemasys65.27%ICUSeaStar Medical1.69%VVOSVivos Therapeutics26.35%Insider OwnershipCompanyInsider OwnershipCOCHEnvoy Medical58.90%FEMYFemasys11.54%ICUSeaStar Medical1.30%VVOSVivos Therapeutics3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOCHEnvoy Medical3421.52 million8.85 millionNot OptionableFEMYFemasys3032.58 million28.82 millionNot OptionableICUSeaStar Medical227.92 million27.55 millionNot OptionableVVOSVivos Therapeutics1605.89 million5.71 millionOptionableICU, COCH, FEMY, and VVOS HeadlinesRecent News About These CompaniesVivos Therapeutics, Inc: Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational UpdateAugust 20 at 5:34 AM | finanznachrichten.deVivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational UpdateAugust 19 at 4:20 PM | globenewswire.comVivos Therapeutics, Inc. Announces Upcoming Release of Second Quarter 2025 Financial Results and Conference CallAugust 19 at 8:51 AM | quiverquant.comQVivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference CallAugust 19 at 8:30 AM | globenewswire.comVivos Therapeutics Delays Q2 2025 10-Q FilingAugust 14, 2025 | msn.comVivos Therapeutics (VVOS) Projected to Post Earnings on WednesdayAugust 12, 2025 | americanbankingnews.comVivos Therapeutics (NASDAQ:VVOS) Stock Rating Lowered by Wall Street ZenAugust 12, 2025 | americanbankingnews.comVivos Therapeutics Adds to Management Team to Support Expansion and GrowthJuly 30, 2025 | finance.yahoo.comVivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral Appliance - MorningstarJuly 2, 2025 | morningstar.comMVivos Therapeutics Inc. (VVOS) Stock Price Today - WSJJuly 2, 2025 | wsj.comVivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral ApplianceJuly 1, 2025 | taiwannews.com.twTVivos Therapeutics stock soars after Medicare approves VidaSleep oral applianceJuly 1, 2025 | in.investing.comVivos Therapeutics Shares Skyrocket After Medicare Greenlights VidaSleep Oral DeviceJuly 1, 2025 | msn.comVivos Therapeutics Secures CMS Approval for VidaSleep™ Oral Appliance, Expanding Access to Sleep Apnea TreatmentJuly 1, 2025 | quiverquant.comQNew Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in ChildrenJune 26, 2025 | finance.yahoo.comNew Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in ChildrenJune 26, 2025 | globenewswire.comVivos Therapeutics, Inc: Vivos Therapeutics Completes Acquisition of The Sleep Center of NevadaJune 11, 2025 | finanznachrichten.deVivos Therapeutics Completes Acquisition of The Sleep Center of NevadaJune 11, 2025 | finance.yahoo.comVivos Therapeutics Completes Acquisition of The Sleep Center of Nevada, Expanding OSA Diagnostic and Treatment CapabilitiesJune 11, 2025 | quiverquant.comQVivos Therapeutics Secures $1.1M Convertible NoteMay 23, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 2025Why the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 20255 Stocks to Buy in August With Tremendous Upside PotentialBy Thomas Hughes | July 31, 2025D-Wave, SuperQ, and Verge: A New Path Forward for Quantum?By Nathan Reiff | July 28, 2025RSI Stock Soars 22% On Q2 Blowout—Will PENN Match the Momentum?By Nathan Reiff | August 7, 2025ICU, COCH, FEMY, and VVOS Company DescriptionsEnvoy Medical NASDAQ:COCH$1.27 +0.06 (+4.96%) Closing price 03:59 PM EasternExtended Trading$1.24 -0.03 (-2.44%) As of 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.Femasys NASDAQ:FEMY$0.62 -0.05 (-7.42%) Closing price 03:58 PM EasternExtended Trading$0.62 0.00 (0.00%) As of 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.SeaStar Medical NASDAQ:ICU$0.80 0.00 (0.00%) Closing price 03:58 PM EasternExtended Trading$0.81 +0.01 (+0.75%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.Vivos Therapeutics NASDAQ:VVOS$4.14 -0.13 (-3.04%) Closing price 03:58 PM EasternExtended Trading$4.18 +0.04 (+0.85%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Target: Missing the Mark in 2025—Downtrend May Continue Renaissance Hedge Fund Adds NVIDIA, Follows Buffett Into UNH Archer's Flight Milestones & Defense Wins Excite Wall Street Home Depot Holds Gains After Narrow Q2 Misses 2 Powerful Forces Now Back Intel's Turnaround The Case for Buying NVIDIA Stock Ahead of the Robotics Surge Medtronic: The Opportunity Gets Healthier for Income Investors Tesla's Breakout: Why This Rally Looks Far From Over Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.